登录/ 注册

Unusual Whales has partnered with @Temaetfs , & their $HRTS ETF, the GLP-1 ETF, to give you the $LLY earnings. Eli Lilly says sales of its weight loss drug Zepbound rose to $1.2 billion. It says full-year revenue could top $46 billion. See $HRTS ETF

08-09 01:08

null source: https://x.com/unusual_whales/status/1821594467079790807

利好

利空

更多新闻 "$lly"

8月 10 日
We have partnered with @temaetfs for $LLY and $NOVO earnings’ week. Here is the $HRTS ETF’s CIO breaking down for the quarter of $LLY. Find out more about the $HRTS GLP-1 ETF here
利好
利空
8月 09 日
Eli Lilly, $LLY, finished up over 9% today after reporting better than expected earnings. Unusual Whales has partnered with @Temaetfs, & their $HRTS ETF, the GLP-1 ETF, with exposure to $LLY and $NOVO. Learn more on $HRTS
利好
利空
8月 08 日
Stocks to Watch Today: LLY, WBD, and AMAT
利好
利空
8月 08 日
Unusual Whales has partnered with @Temaetfs , & their $HRTS ETF, the GLP-1 ETF, to give you the $LLY earnings. $LLY reported: - Revenue: of $11.3 billion, est: $10 billion - EPS: $3.92, est: $2.70 See $HRTS ETF for exposure to weight loss drug stocks
利好
利空
8月 08 日
Eli Lilly and Company (LLY) Shines in Q2 with $11.30 B Revenue, 68% EPS Growth
利好
利空
8月 08 日
Unusual Whales has partnered with @Temaetfs & their $HRTS, the GLP-1 ETF, for earnings of Eli Lilly, $LLY! $LLY has earnings tomorrow, with a 6.16% ($47.59) implied move, the largest in 8 quarters. See $HRTS ETF for exposure to weight loss drug stocks
利好
利空
8月 07 日
Unusual Whales has partnered with @Temaetfs & their $HRTS, the GLP-1 ETF, for earnings of Eli Lilly, $LLY, & Novo Nordisk, $NOVO. $NOVO's expected revenue is $10.8 billion, previous $10.01 billion. See $HRTS ETF for exposure to weight loss drug stocks
利好
利空
6月 25 日
Stocks to Watch Today: CCL, LLY, and DLTR
利好
利空
2月 08 日
LLY vs NVO: Which One is Likely to Become a $1T Company First
利好
利空
2月 06 日
Eli Lilly (LLY) Surpasses Expectations with $9.35 Billion in Q4 Revenue
利好
利空

更多新闻 "$lly"